टेम्सिरोलिमस के इंटरैक्शन

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Temsirolimus The use of concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. (कार्बामाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

…physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

At the discretion of the physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting… (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

…physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

…physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

…physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

…physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in persons with known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any other component (including the excipients) of TORISEL. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Drug Interactions Effect of Temsirolimus on CYP2D6 or CYP3A The concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of temsirolimus was co-administered. (टेम्सिरोलिमस लेबल, दवाओं के इंटरैक्शन)